Hypertrophic Cardiomyopathy Clinical Trial Landscape
Data updated: May 20, 2026
55 clinical trials tracked since 2008
Hypertrophic Cardiomyopathy is being studied across 55 clinical trials registered since 2008, with 23 programs currently active. The competitive pipeline includes 9 active Phase 3 trials, 10 active Phase 2 trials, and 2 active Phase 1 trials. Top industry sponsors include Shandong Suncadia Medicine Co., Ltd., Cytokinetics, Bristol-Myers Squibb.
23 active
/
55 total (since 2008)
2
Phase 1 Active
10 total
10
Phase 2 Active
25 total
9
Phase 3 Active
18 total
6
Phase 4 Active
9 total
Top Industry Sponsors
Sorted by active Active Done Failed
Shandong Suncadia Medicine Co., Ltd. 4 3 0
Cytokinetics 3 4 0
Bristol-Myers Squibb 1 2 0
Imbria Pharmaceuticals, Inc. 1 1 0
Bayer 1 0 0
+ 4 more sponsors — see full table below
Featured Phase 3 Trials
NCT07023341 ACTIVE NOT RECRUITING
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bayer n=36
NCT06412666 RECRUITING
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Cytokinetics n=55
NCT05182658 ACTIVE NOT RECRUITING
Empagliflozin in Hypertrophic Cardiomyopathy
National Institute of Cardiology, Warsaw, Poland n=250
NCT06481891 RECRUITING
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals n=500
NCT06081894 ACTIVE NOT RECRUITING
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Cytokinetics n=500
+ 13 more Phase 3 trials — see full database below
Hypertrophic Cardiomyopathy — Trials Started by Year (last 10 years)
2016 1
2017 1
2018 6
2019 2
2020 3
2021 4
2022 5
2023 5
2024 6
2025 10
2026 3
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Shandong Suncadia Medicine Co., Ltd. 7
Cytokinetics 7
Bristol-Myers Squibb 3
Imbria Pharmaceuticals, Inc. 2
Bayer 1
Tenaya Therapeutics 1
Lexicon Pharmaceuticals 1
Edgewise Therapeutics, Inc. 1
MyoKardia, Inc. 3
Corxel Pharmaceuticals 2
Active Trials by Phase
Phase 1 2
Phase 2 10
Phase 3 9
Phase 4 6
Enrollment Size Distribution
1-50 21
51-200 23
201-500 9
501-1k 2
1k+ 0
All Industry Sponsors
Sorted by active Active Done Failed
Shandong Suncadia Medicine Co., Ltd. 4 3 0
Cytokinetics 3 4 0
Bristol-Myers Squibb 1 2 0
Imbria Pharmaceuticals, Inc. 1 1 0
Bayer 1 0 0
Tenaya Therapeutics 1 0 0
Lexicon Pharmaceuticals 1 0 0
Edgewise Therapeutics, Inc. 1 0 0
MyoKardia, Inc. 0 3 0
NCT07023341 ACTIVE NOT RECRUITING
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bayer n=36
NCT06412666 RECRUITING
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Cytokinetics n=55
NCT05182658 ACTIVE NOT RECRUITING
Empagliflozin in Hypertrophic Cardiomyopathy
National Institute of Cardiology, Warsaw, Poland n=250
NCT06481891 RECRUITING
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals n=500
NCT06081894 ACTIVE NOT RECRUITING
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Cytokinetics n=500
NCT04848506 ENROLLING BY INVITATION
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Cytokinetics n=900
NCT07202897 NOT YET RECRUITING
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Rennes University Hospital n=532
NCT07021976 RECRUITING
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd. n=216
NCT06873828 NOT YET RECRUITING
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Yonsei University n=100
NCT05186818 COMPLETED
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Cytokinetics n=282
NCT03723655 COMPLETED
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
Bristol-Myers Squibb n=314
NCT06116968 COMPLETED
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Corxel Pharmaceuticals n=40
NCT05767346 COMPLETED
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Cytokinetics n=175
NCT05174416 COMPLETED
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
LianBio LLC n=81
NCT05366101 COMPLETED
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
Newcastle-upon-Tyne Hospitals NHS Trust n=168
NCT03470545 COMPLETED
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. n=251
NCT02291237 TERMINATED
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Gilead Sciences n=172
NCT00821353 COMPLETED
Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
National Institute of Cardiology, Warsaw, Poland n=90
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only